Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for Two Cancer Drug Candidates
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Drug
Novartis’ Lutathera Meets Primary Endpoint in Phase III Trial for GEP-NETs
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that a Phase III trial for its...
AffaMed Therapeutics’ Luminate Receives Clinical Trial Approval for Dry AMD in China
AffaMed Therapeutics, a China-based biotech firm, has announced the receipt of its first clinical trial...
Hansoh Pharmaceutical Gets NMPA Approval for HS-20105 Clinical Study in Solid Tumors
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a China-based pharmaceutical company, has announced that it...
Shanghai Junshi’s Tuoyi Meets Primary Efficacy Endpoint in Phase III Melanoma Study
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...
Abbisko Therapeutics Gets NMPA Approval for Irpagratinib Combination Study in HCC
Shanghai-based biotechnology company Abbisko Therapeutics Co., Ltd (HKG: 2256) has received approval from the National...
Hepagene Therapeutics’ HPG7233 Receives US FDA IND Approval for NASH Treatment
Hong Kong-based biopharmaceutical company Hepagene Therapeutics Inc. has announced that the US Food and Drug...
Abbisko Therapeutics’ Irpagratinib Receives FDA Clearance for Phase I Study in HCC
Shanghai-based biotechnology company Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...
Sino Biopharmaceutical Submits IND Application for AT2R Antagonist TRD205 to FDA
Sino Biopharmaceutical Ltd (HKG: 1177), a leading China-based biotech company, has announced the filing of...
Fosun Pharma’s Serplulimab Approved for Esophageal Squamous Cell Carcinoma and Grafalon for GvHD Study
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has issued updates on the development statuses...
CDC Provisionally Recommends Pfizer’s Abrysvo for Maternal Immunization Against RSV
The US Centers for Disease Control and Prevention (CDC) has issued a provisional recommendation for...
Boehringer Ingelheim and Eli Lilly’s Jardiance Wins FDA Approval for CKD Prevention
Boehringer Ingelheim (BI) and Eli Lilly (NYSE: LLY) have received regulatory approval from the US...
MSD’s Keytruda Meets Endpoints in Urothelial Carcinoma Trial but Misses in NSCLC Study
Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading global pharmaceutical company, last week released...
Betta Pharmaceuticals’ CFT8919 Accepted for Review by China’s NMPA for EGFR L858R Solid Tumors
Betta Pharmaceuticals Co., Ltd (SHE: 300558), a China-based pharmaceutical company, has announced that the National...
CNIPA Upholds Alynlam Pharmaceutical’s PCSK9 siRNA Patent Against Junshi Biosciences Challenge
The China National Intellectual Property Administration (CNIPA) has rejected a challenge filed by Junshi Biosciences...
Sanofi’s Dupixent Secures NMPA Approval for Pruritigo Nodosa Treatment in China
France-based pharmaceutical company Sanofi (NASDAQ: SNY) has announced that it has received another indication approval...
Suzhou Zelgen Biopharmaceuticals’ ZG005 Receives NMPA Approval for Solid Tumor Trial
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a China-based pharmaceutical company, has announced that it...
Antengene’s Anti-CD24 Antibody ATG-031 Gets Green Light for Phase I Study at MD Anderson
Antengene Corporation Ltd (HKG: 6996), a China-based biopharmaceutical company, has announced that the Institutional Review...
Mabwell Bioscience’s 9MW3011 Earns US FDA Fast Track Designation for Polycythemia Vera Treatment
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that it...
Novartis’s Aimovig Approved by China’s NMPA for Preventive Migraines Treatment
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that it has received market approval from...